Shorts

Charles S. Kamen, PhD, MPH, suggests that clinicians should anticipate a greater sensitivity to cues of rejection among patients that are sexual or gender minorities, which would prompt them to make a greater effort to include a patient’s support people in decision-making processes.

1:13

Highlighting Decision-Making Inclusion for LGBTQ+ Loved Ones/Caregivers

4 months ago

Charles S. Kamen, PhD, MPH

1:30

Addressing the Burden of Disclosure for LGBTQ+ Patients in Oncology Care

4 months ago

Charles S. Kamen, PhD, MPH

1:19

Practice With Cultural Humility: Treating LGBTQ+ Patients with Cancer

4 months ago

Charles S. Kamen, PhD, MPH

Daniel Peters, MD, discussed 3 main pillars he uses to guide practice when treating patients with acute myeloid leukemia (AML); patient health, treatment goals, and molecular testing (genomics).

0:45

Guiding AML Treatment Stategy: Three Pillars For Clinicians

5 months ago

Daniel Peters, MD

Cary Gross, MD, discussed results from a study he coauthored regarding quality of care outcomes among patients treated with cancer during incarceration or within the year following release. Specifically, he discussed a need for the re-engagement of patients with cancer who were recently released from incarceration in the health care system and programs such as the Transitions Programs, which aim to fulfill that need.

0:53

Engaging Patients With Cancer Into Health Care Systems After Incarceration

5 months ago

Cary Gross, MD

Thomas Marron, MD, discussed a presentation he gave at the Chemotherapy Foundation Symposium (CFS) titled, "Stage I-III Is Not What It Used to Be".

0:51

Immune System Training: Explicating Perioperative Immunotherapy Use

5 months ago

Thomas Marron, MD, PhD

Rona Yaeger, MD, discussed key takeaways from her presentation titled, “Targeting BRAF, KRAS, and HER2 in GI Tumors” in an interview at the 43rd Annual Chemotherapy Foundation Symposium (CFS) in New York, NY.

0:41

Testing For Mutational Status Might Improve Colorectal Cancer Survival

5 months ago

Rona Yaeger, MD

Michael Barish, PhD, discussed the application of a scorpion venom-derived chlorotoxin in treating 4 patients with glioblastoma in an interview with CancerNetwork.

1:01

Exploring The Applicability of Scorpion Venom in Glioblastoma Treatment

5 months ago

Michael Barish, PhD

Toru Kondo, PhD, discussed his presentation titled, "Evaluating EVA1-ADC as a Novel Therapeutic Strategy for Eliminating Glioblastoma-Initiating Cells," that he gave at World ADC

0:54

EVA1-Targeting ADCs May Reduce AEs vs Anti-CD133 Agents in Glioblastoma

5 months ago

Toru Kondo, PhD

0:44

ADCs May Be Emerging As Preferred Backbone in HER2+/HR+ Breast Settings

5 months ago

Aditya Bardia, MD, MPH, FASCO

Patients with medullary thyroid carcinoma or the MEN type 2 genetic disorder should not start GLP-1 agents for risk of insulin secretion and severe hypoglycemia.

0:37

When Should Patients with NETs Be Advised Not To Take GLP-1 Agents?

5 months ago

Joseph Dillon, MB, BCh, BAO

Micheal C. Soulen, MD, discussed his presentation of the phase 2 CapTemY90 trial assessing the combination of radioembolization and chemotherapy in patients with liver-dominant NETs at the 2025 North American Neuroendocrine Tumor Symposium.

0:37

Y90/Radiosensitizing Chemotherapy Regimen Feasible in Liver-Dominnat NETs

5 months ago

Michael C. Soulen, MD

In an interview with CancerNetwork®, Eyub Akdemir, MD, radiation oncologist at Miami Cancer Institute, discussed findings from a single-institution retrospective study evaluating the timing and predictors of severe lymphopenia in patients with lung cancer treated with definitive proton chemoradiotherapy.

0:55

Proton Chemoradiotherapy May Reduce Severe Lymphopenia Rates

6 months ago

Eyub Akdemir, MD

CancerNetwork spoke with Udhayvir S. Grewal, MBBS, assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, about an analysis of the Neuroendocrine Tumors - Patient-Reported Outcomes (NET-PRO) study he presented at the 2025 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium.

0:44

NET-PRO: Younger NET Population Experiences More Significant AEs

6 months ago

Udhayvir S. Grewal, MD

CancerNetwork® spoke with Mary Maluccio, MD, MPH, FACS, about her presentation on a PRRT–naive cohort of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who received the investigational SSTR–targeted alpha therapy 212Pb-DOTAMTATE at NANETS.

0:39

Examining 212Pb-DOTAMTATE Clinical Outcomes in PRRT-Naive GEP-NETs

6 months ago

Mary Maluccio, MD, MPH, FACS

According to Stefano Partelli, MD, PhD, quality metrics in pNET surgery are fundamentally tied to the experience and volume of the treating center, given the high risk of complications and mortality.

1:13

Predicting Early Post-Surgical Recurrence in pNETs

6 months ago

Stefano Partelli, MD, PhD

Julie Hallet, MD, MSc, FRCSC, stated that the core mission of initiatives like CUTNETs is to standardize care and mitigate the high risks associated with complex operations on neuroendocrine tumors.

1:06

CUTNETs: Spotlighting a Collaboration Between Surgery and NET Oncology

6 months ago

Julie Hallet, MD, MSc, FRCSC

Twelve patients in the CARTITUDE-1 trial maintained a cancer-free, MRD-negative status for 5 years without maintenance, fulfilling a proposed curative definition for a "cure".

0:59

Including "Cure" in the Multiple Myeloma Treatment Dialogue

6 months ago

Sundar Jagannath, MD

David Rimm, MD, PhD, said that pathologists play a crucial role in educating oncologists about the "science behind the assay," helping oncologists understand the robustness, sensitivity, and specificity of different tests, which can have varying levels of accuracy and precision.

0:39

Looking Beyond Genomics in Precision Medicine for Cancer Care

7 months ago

Elizabeth Kessler, MD highlighted a new target that oncologists should be aware of: the combination of niraparib, abiraterone, and prednisone in combination with an ADT backbone. which has shown a progression-free survival benefit and a trend toward an overall survival benefit.

1:29

Spotlighting Imaging/Therapuetic Advances Hormone Sensitive Prostate Cancer

7 months ago

Ben Garmezy, MD(+1 more)

0:30

Dosing Considerations for Optimizing Ruxolitinib Efficacy in Myelofibrosis

7 months ago

Francesca Palandri, MD, PhD

Manojkumar Bupathi, MD, MS, executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute, spoke with different experts about their localized therapy perspectives during the morning sessions from World GU.

1:22

Highlighting Advances in Localized Therapy for Genitourinary Cancers

7 months ago

Manojkumar Bupathi, MD, MS(+3 more)

Kerry R. Schaffer, MD, assistant professor in the Department of Medicine at the Vanderbilt Ingram Cancer Center and genitourinary oncologist, discussed the evolving role of radioligand therapy and imaging criteria in prostate cancer at the 2025 World Conference on Genitourinary Cancers.

1:02

Advancing Radioligand Therapy and Imaging Criteria in Prostate Cancer

7 months ago

Benjamin Garmezy, MD(+1 more)

In patients with ES-SCLC, a population that has historically had limited treatment options after initial platinum-based chemotherapy, the recent accelerated approval of tarlatamab marks a significant advancement.

0:53

Offering Hope for Relapsed Brain Metastatic ES-SCLC With Tarlatamab

7 months ago

Bingnan Zhang, MD, MBA

Although more recent drugs with a different mechanism of action are continuing to improve the treatment landscape, there is still work to be done to improve quality of life and achieve a cure for patients with chronic myeloid leukemia.

0:35

Outlining Chronic Myeloid Leukemia Advancements Through the Decades

7 months ago

Jorge E. Cortes, MD

A multidisciplinary discussion may help in developing optimal treatment strategies for genitourinary cancers cases not covered by standard guidelines.

1:30

Optimizing Care Through Multidisciplinary Collaboration in GU Cancers

7 months ago

Benjamin Garmezy, MD(+1 more)

Ronald Bleday, MD, colorectal surgeon, touched upon his experience with an Enhanced Recovery after Surgery perioperative approach for pain management for patients with colorectal cancer.

0:34

Managing Narcotic Use in Perioperative CRC Care

8 months ago

Ronald Bleday, MD

Michael William Kendall, MD, a primary care physician specializing in cancer survivorship, emphasized the importance of timely discussions surrounding sexual health.

1:30

Discussing Sexual Health in Oncologic Practice

8 months ago

Micheal William Kendall, MD

While weight loss can be a compelling factor for a cancer diagnosis, Denise B. Reynolds, RD, does not promote weight loss during active treatment, instead, focusing on helping patients maintain their weight and nutritional status.

1:17

Managing Cancer-Related Adverse Effects Through Nutrition and Wellness

8 months ago

Denise B. Reynolds, RD

McFarland emphasized the need for a new approach, moving past the "see one, do one, teach one" model common among many oncologists.

1:19

Bridging the Psycho-Oncology Gap in Body Image Management

8 months ago

Daniel C. McFarland, DO

Shorts

Trending on CancerNetwork

Dose Modification Strategies in EGFR Mutated Metastatic Non-Small Cell Lung Cancer

Utilizing AI Algorithms to Inform Breast Cancer Chemoprevention Strategies

Novel Drug Class is Convenient and Meaningful in Multiple Myeloma Landscape

What Role Will The EV-304 Regimen Occupy in The Bladder Cancer Paradigm?

Zongertinib Yields Enduring Activity in Frontline HER2+ NSCLC Trial